ADC Therapeutics SA Common Shares (ADCT)
How ADCT actually reacts to news — the realized, point-in-time move the market made, measured across 430 labeled events over the last three years with zero look-ahead.
ADCT’s median reaction, across the day.
Half of all ADC Therapeutics SA Common Shares news events land between -1.49% and +2.17% at 30 minutes.
Reaction stats as of 2026-08-13. Reaction = percent move vs. the price at the news timestamp.
Email me when ADCT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ADCT’s baseline. Nothing else.
Get “How ADCT reacts to news” as a PDF.
A free one-page summary: ADCT’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent ADCT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates | Press release | PR Newswire | -4.66% | +5.00% | |
| Form 10-Q ADC Therapeutics SA For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.49% | -0.98% | |
| Form 8-K ADC Therapeutics SA For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -4.66% | +5.00% | |
| Form S-8 ADC Therapeutics SA | SEC filing · Form S-8 | SEC EDGAR | +0.49% | -0.98% | |
| ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 | Press release | PR Newswire | +1.87% | +5.61% | |
| Form 8-K ADC Therapeutics SA For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +4.17% | |
| ADC Therapeutics Announces New Employee Inducement Grant | Press release | PR Newswire | +2.65% | +5.31% | |
| ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial | Press release | PR Newswire | +3.77% | +0.94% | |
| ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities | Press release | PR Newswire | +2.70% | -3.60% | |
| Bronstein, Gewirtz & Grossman, LLC (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -5.73% | |
| Form 8-K ADC Therapeutics SA For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +2.70% | -3.60% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.32% | +0.88% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.48% | +3.81% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.80% | -1.80% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +1.80% | -1.80% | |
| ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +4.22% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.48% | +1.94% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.46% | -1.85% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +1.83% | +0.46% | |
| ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -2.80% | +2.80% | |
| ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Press release | PR Newswire | +5.97% | -1.49% | |
| Form 8-K ADC Therapeutics SA For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +5.97% | -1.49% | |
| Form 8-K ADC Therapeutics SA For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -1.91% | |
| ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates | Press release | PR Newswire | +2.10% | +2.79% | |
| Form 10-Q ADC Therapeutics SA For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.41% | +0.80% | |
| Form 8-K ADC Therapeutics SA For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | +2.79% | |
| ADC Therapeutics Makes Grants to New Employees Under Inducement Plan | Press release | PR Newswire | +0.53% | +1.32% | |
| ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 | Press release | PR Newswire | +2.32% | -3.09% | |
| Form DEF 14A ADC Therapeutics SA For: Jun 01 | SEC filing · Form DEF | SEC EDGAR | +0.82% | -0.23% | |
| Form DEFA14A ADC Therapeutics SA | SEC filing · Form DEFA14A | SEC EDGAR | +0.82% | -0.23% | |
| Form PRE 14A ADC Therapeutics SA For: Jun 01 | SEC filing · Form PRE | SEC EDGAR | +1.61% | +2.15% | |
| ADC Therapeutics Announces New Employee Inducement Grant | Press release | PR Newswire | +0.14% | +3.00% | |
| Form EFFECT ADC Therapeutics SA | SEC filing · Form EFFECT | SEC EDGAR | -0.94% | -3.07% | |
| ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update | Press release | PR Newswire | -4.29% | +5.73% | |
| Form 10-K ADC Therapeutics SA For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.63% | +2.95% | |
| Form 8-K ADC Therapeutics SA For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -4.29% | +5.73% | |
| Form ARS ADC Therapeutics SA For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.63% | +2.95% | |
| Form S-3 ADC Therapeutics SA | SEC filing · Form S-3 | SEC EDGAR | +0.63% | +2.95% | |
| ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 | Press release | PR Newswire | +0.00% | +0.00% | |
| ADC Therapeutics Makes Grants to New Employees Under Inducement Plan | Press release | PR Newswire | +0.00% | +0.00% | |
| ADC Therapeutics to Participate in March Investor Conferences | Press release | PR Newswire | +1.11% | -0.68% | |
| ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement | Press release | PR Newswire | +0.97% | +7.30% | |
| Form 8-K ADC Therapeutics SA For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | +7.30% | |
| ADC Therapeutics Makes Grants to New Employees Under Inducement Plan | Press release | PR Newswire | -0.25% | -0.76% | |
| Form 8-K ADC Therapeutics SA For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.37% | |
| ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates | Press release | PR Newswire | +0.51% | +1.10% | |
| ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.97% | -1.38% | |
| Form 8-K ADC Therapeutics SA For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +1.10% | |
| ADC Therapeutics Announces New Employee Inducement Grant | Press release | PR Newswire | -1.97% | -0.56% | |
| Form EFFECT ADC Therapeutics SA | SEC filing · Form EFFECT | SEC EDGAR | -1.54% | -0.47% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ADCT section they belong to.
More of the dataset.
ADCT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ADC Therapeutics SA Common Shares's median reaction calculated?
Every labeled ADCT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 430 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ADCT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-13.
Does ADCT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.